Resultados financieros en millones de dólares estadounidenses. El ejercicio fiscal es febrero - enero.
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Ingresos
50
50
52
66
81
65
Crecimiento de los Ingresos (YoY)
0%
-4%
-21%
-19%
25%
48%
Costo de los ingresos
25
25
28
35
42
27
Utilidad bruta
25
24
24
30
39
37
Venta, General y Administración
18
15
15
17
8
18
Investigación y Desarrollo
--
--
--
--
--
--
Gastos de Operación
17
17
19
22
17
21
Otras Ingresos (Gastos) No Operativos
--
0
0
0
0
0
Ingreso antes de impuestos
6
6
2
-8
21
15
Gasto por Impuesto a la Renta
0
0
0
0
5
3
Ingreso Neto
6
6
2
-10
15
11
Crecimiento de la Utilidad Neta
50%
200%
-120%
-167%
36%
267%
Acciones en Circulación (Diluidas)
451.95
453.73
454.1
457.18
460.95
458.8
Cambio de Acciones (YoY)
0%
0%
-1%
-1%
0%
0%
EPS (Diluido)
0.01
0.01
0
-0.02
0.03
0.02
Crecimiento de EPS
-8%
165%
-124%
-164%
42%
202.99%
Flujo de efectivo libre
8
10
0
3
4
11
Flujo de efectivo libre por acción
--
--
--
--
--
--
Margen bruto
50%
48%
46.15%
45.45%
48.14%
56.92%
Margen de operación
14%
12%
7.69%
12.12%
27.16%
23.07%
Margen de beneficio
12%
12%
3.84%
-15.15%
18.51%
16.92%
Margen de flujo de caja libre
16%
20%
0%
4.54%
4.93%
16.92%
EBITDA
11
10
9
14
27
19
Margen de EBITDA
22%
20%
17.3%
21.21%
33.33%
29.23%
D&A para EBITDA
4
4
5
6
5
4
EBIT
7
6
4
8
22
15
Margen de EBIT
14%
12%
7.69%
12.12%
27.16%
23.07%
Tasa de Impuesto Efectiva
0%
0%
0%
0%
23.8%
20%
Estadísticas clave
Cierre Anterior
$0.3516
Precio de apertura
$0.3516
Rango del día
$0.3516 - $0.3516
Rango de 52 semanas
$0.2383 - $0.4236
Volumen
20.0K
Volumen promedio
2.2K
EPS (TTM)
0.02
Rendimiento de dividendos
--
Cap. de mercado
$151.8M
¿Qué es EKF DIAGNOSTICS HOLDINGS PLC?
EKF Diagnostics Holdings Plc is a vitro diagnostics company, which engages in the designs and manufactures diagnostic equipment for use within point-of-care settings. The company is headquartered in Penarth, South Glamorgan and currently employs 297 full-time employees. The company went IPO on 2002-06-05. The firm develops and produces in-vitro diagnostic (IVD) devices and tests designed for use at or near the patient’s location. The company provides a suite of products for diabetes management, including glucose monitoring systems and associated consumables. The company offers devices, supplies, and consumables for measuring hemoglobin levels, including tools for detecting hemoglobin variants. The company also develops and supplies diagnostic and therapeutic enzymes, proteins, reagents, and biomaterials. The company provides precision fermentation, custom bioprocessing, and contract manufacturing services for pharmaceuticals and other biological products. The company supplies beta-hydroxybutyrate (HB) products used in ketone detection to support the diagnosis of diabetic ketoacidosis and other clinical conditions.